Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Biomanufacturing Productivity Improvement Support ServiceBiorefinery
Applicable field (uses covered by this announcement)
バイオ化学品原料BiofuelsSAFPharmaceuticalsFoodFibersMaterial
Launch date2026年1月6日（協働開始・最適化実験開始、実績）
What the company reported numerically
Quantitative Effects
生産性向上およびコストダウンを目指す（数値はNot disclosed）
Relationship between the counterparty and the company
Human Metabolome Technologies,Inc.6090
Relationship with the Company
HMTとGEIがバイオ化学品生産の最適化に向けて協働する関係。資本関係・人的関係の記載はない。
CounterpartyGreen Earth Institute株式会社（証券コード9212、東証グロース）
本社：東京都新宿区新宿３丁目５番６号、代表取締役CEO：伊原智人、事業内容：バイオものづくり技術開発・サービス事業
Impact on Business Performance
The impact of this matter on financial results is minor
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Biomanufacturing Productivity Improvement Support Service, Biorefinery |
| Counterparty | Green Earth Institute株式会社（証券コード9212、東証グロース） |
| Counterparty overview | 本社：東京都新宿区新宿３丁目５番６号、代表取締役CEO：伊原智人、事業内容：バイオものづくり技術開発・サービス事業 |
| Relationship with the Company | HMTとGEIがバイオ化学品生産の最適化に向けて協働する関係。資本関係・人的関係の記載はない。 |
| Launch date | 2026年1月6日（協働開始・最適化実験開始、実績） |
| Applicable area | バイオ化学品原料, Biofuels, SAF, Pharmaceuticals, Food, Fibers, Material |
| Quantitative Effects | 生産性向上およびコストダウンを目指す（数値はNot disclosed） |
| Impact on Business Performance | The impact of this matter on financial results is minor |
Items this document does not state (10)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.GEIの菌株遺伝子組換え技術・スケールアップ最適化技術と、HMTのメタボローム解析技術を組み合わせ、代謝のボトルネックとなる反応経路を特定して発酵プロセスを最適化するため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.